Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | GSK3A | P49840 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6554046 | 0.89 | ALDH1A1 (0.47) | TAAR1F2RL1MAOBCALM1SMN1; SMN2 | |
| SCHEMBL1272898 | 0.88 | CALM1 (0.56) | TAAR1F2RL1MAOBCALM1SMN1; SMN2 | |
| SCHEMBL11044744 | 0.85 | CALM1 (0.53) | TAAR1F2RL1MAOBCALM1GSK3A | |
| SCHEMBL9825782 | 0.83 | KDM4E (0.59) | SMN1; SMN2ALDH1A1TP53CYP3A4CA12 | |
| SCHEMBL9206133 | 0.82 | GFER (0.36) | TAAR1MAOBCYP3A4TSHRCA12 | |
| SCHEMBL910342 | 0.80 | NQO1 (0.54) | SMN1; SMN2ALDH1A1TSHRCA12CA1 | |
| SCHEMBL834551 | 0.79 | TAAR1 (0.73) | TAAR1F2RL1MAOBCALM1SIGMAR1 | |
| SCHEMBL5542339 | 0.79 | CYP19A1 (0.48) | CALM1ALDH1A1CYP3A4TSHR | |
| SCHEMBL11212989 | 0.79 | TAAR1 (0.55) | TAAR1F2RL1MAOBCALM1SIGMAR1 | |
| SCHEMBL18245284 | 0.79 | TAAR1 (0.55) | TAAR1F2RL1MAOBCALM1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 627 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | claimed |
| WO-2020055678-A1 | MENAQUINOL COMPOSITIONS AND METHODS OF TREATMENT | Epizon Pharma, Inc. (US) | 2020-03-19 | — | — | WO | claimed |
| US-20200079718-A1 | Menaquinol Compositions and Methods of Treatment | Epizon Pharma, Inc. (US) | 2020-03-12 | — | — | US | claimed |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | claimed |
| US-20060241308-A1 | Probe for measuring phytase activity | BERRY & ASSOCIATES, INC. | 2006-10-26 | — | — | US | claimed |
| US-20040186151-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-23 | — | — | US | claimed |
| WO-2004071448-A2 | SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | TRANSTECH PHARMA INC. (US) | 2004-08-26 | — | — | WO | claimed |
| EP-0560267-B1 | Isosteric antiherpes peptide derivatives | BOEHRINGER INGELHEIM CA LTD (CA) | 1998-08-19 | — | — | EP | claimed |
| EP-0767671-A1 | METHOD OF COMBATING ACYCLOVIR-RESISTANT HERPES SIMPLEX VIRAL INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1997-04-16 | — | — | EP | claimed |
| US-5574015-A | Isosteric antiherpes peptide derivatives | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1996-11-12 | — | — | US | claimed |
| WO-1994025046-A1 | METHOD OF COMBATING ACYCLOVIR-RESISTANT HERPES SIMPLEX VIRAL INFECTIONS | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-11-10 | — | — | WO | claimed |
| WO-1993018056-A1 | ISOSTERIC ANTIHERPES PEPTIDE DERIVATIVES | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-16 | — | — | WO | claimed |
| EP-0560267-A1 | Isosteric antiherpes peptide derivatives | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-15 | — | — | EP | claimed |
| EP-0480918-A1 | REDUCED SIZE LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1992-04-22 | — | — | EP | claimed |
| EP-0443559-A2 | HIV protease inhibiting agents | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1991-08-28 | — | — | EP | claimed |
| EP-0480918-A4 | REDUCED SIZE LHRH ANALOGS. | ABBOTT LAB (US) | 1991-06-04 | — | — | EP | claimed |
| EP-0417454-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1991-03-20 | — | — | EP | claimed |
| WO-1989007451-A1 | REDUCED SIZE LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1989-08-24 | — | — | WO | claimed |
| EP-0328089-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | claimed |
| US-12043639-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| EP-4384508-A2 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2024-06-19 | — | — | EP | disclosed |
| US-11970512-B2 | Amphotericin B derivatives with improved therapeutic index | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-04-30 | — | — | US | disclosed |
| WO-2024031051-A1 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024006937-A1 | LIPID COMPOSITIONS FOR IN VIVO DELIVERY | Life Technologies Corporation (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20240000966-A1 | Lipid Compositions For In Vivo Delivery | Life Technologies Corporation | 2024-01-04 | — | — | US | disclosed |
| US-11850237-B2 | Compounds and methods for treating influenza | ROMARK LABORATORIES L.C. (US) | 2023-12-26 | — | — | US | disclosed |
| CN-110407898-B | Amphotericin B derivatives with improved therapeutic index | 伊利诺伊大学评议会 | 2023-12-01 | — | — | CN | disclosed |
| US-11603345-B2 | Menaquinol compositions and methods of treatment | Epizon Pharma, Inc. (US) | 2023-03-14 | — | — | US | disclosed |
| WO-2023018990-A2 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2023-02-16 | — | — | WO | disclosed |
| US-20220348530-A1 | Menaquinol Compositions and Methods of Treatment | Epizon Pharma, Inc. (US) | 2022-11-03 | — | — | US | disclosed |
| US-11332427-B2 | Menaquinol compositions and methods of treatment | Epizon Pharma, Inc. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20220056066-A1 | AMPHOTERICIN B DERIVATIVES WITH IMPROVED THERAPEUTIC INDEX | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2022-02-24 | — | — | US | disclosed |
| EP-2445349-B1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | ROMARK LABORATORIES LC (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20210323984-A1 | POL YCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | MOLECULAR TRANSFER, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3895706-A1 | THIAZOLINIDE COMPOUNDS FOR TREATING NON-INFLUENZA VIRAL INFECTIONS | Romark Laboratories, L.C. (US) | 2021-10-20 | — | — | EP | disclosed |
| US-11117920-B2 | Amphotericin B derivatives with improved therapeutic index | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210189433-A1 | AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | Molecular Transfer Inc. | 2021-06-24 | — | — | US | disclosed |
| US-20210177809-A1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | ROMARK LABORATORIES L.C. (US) | 2021-06-17 | — | — | US | disclosed |
| US-11034725-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-11028114-B2 | Amphotericin B derivatives with improved therapeutic index | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-06-08 | — | — | US | disclosed |
| US-10968240-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-10912768-B2 | Compounds and methods for treating influenza | ROMARK LABORATORIES L.C. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20210009494-A1 | Menaquinol Compositions and Methods of Treatment | Epizon Pharma, Inc. (US) | 2021-01-14 | — | — | US | disclosed |
| US-10883118-B2 | Agents for improved delivery of nucleic acids to eukaryotic cells | Molecular Transfer Inc. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10822295-B2 | Menaquinol compositions and methods of treatment | Epizon Pharma, Inc. (US) | 2020-11-03 | — | — | US | disclosed |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200289456-A1 | METHODS FOR INHIBITING TUMORS AND DRUG RESISTANCE | SEQUOIA PHARMACEUTICALS, INC., | 2020-09-17 | — | — | US | disclosed |
| US-20200283478-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| WO-2020055678-A1 | MENAQUINOL COMPOSITIONS AND METHODS OF TREATMENT | Epizon Pharma, Inc. (US) | 2020-03-19 | — | — | WO | disclosed |
| US-20200079718-A1 | Menaquinol Compositions and Methods of Treatment | Epizon Pharma, Inc. (US) | 2020-03-12 | — | — | US | disclosed |
| US-10550153-B2 | Peptide or pharmaceutically acceptable salt thereof, or prodrug thereof | TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES (JP) | 2020-02-04 | — | — | US | disclosed |
| US-RE47786-E1 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES L.C. (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190352316-A1 | POLYCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | MOLECULAR TRANSFER, INC. (US) | 2019-11-21 | — | — | US | disclosed |
| EP-2696678-B1 | AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | MOLECULAR TRANSFER INC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190345187-A1 | AMPHOTERICIN B DERIVATIVES WITH IMPROVED THERAPEUTIC INDEX | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2019-11-14 | — | — | US | disclosed |
| US-20190307730-A1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | ROMARK LABORATORIES L.C. (US) | 2019-10-10 | — | — | US | disclosed |
| US-20190264230-A1 | AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | Molecular Transfer Inc. | 2019-08-29 | — | — | US | disclosed |
| US-10363243-B2 | Compounds and methods for treating influenza | ROMARK LABORATORIES L.C. (US) | 2019-07-30 | — | — | US | disclosed |
| US-10323057-B2 | Amphotericin B derivatives with improved therapeutic index | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-06-18 | — | — | US | disclosed |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | disclosed |
| US-10188605-B2 | Nanoparticles and nanoparticle compositions | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-10174033-B2 | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2019-01-08 | — | — | US | disclosed |
| US-10155780-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2018-12-18 | — | — | US | disclosed |
| US-10138497-B2 | Agents for improved delivery of nucleic acids to eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| EP-1805158-B1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS INC (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-3055030-B1 | AMPHOTERICIN B DERIVATIVES WITH IMPROVED THERAPEUTIC INDEX | UNIV ILLINOIS (US) | 2018-05-02 | — | — | EP | disclosed |
| US-20180078533-A1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | ROMARK LABORATORIES L.C. (US) | 2018-03-22 | — | — | US | disclosed |
| CN-106278965-B | Aryl alkyl asymmetry over cure class compound and its synthetic method and application | 华东师范大学 | 2018-02-23 | — | — | CN | disclosed |
| US-RE46724-E1 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES, L.C. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20180002724-A1 | AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | Molecular Transfer Inc. | 2018-01-04 | — | — | US | disclosed |
| US-9849107-B2 | Compositions and methods for inhibiting cytochrome P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170354636-A1 | METHODS FOR INHIBITING TUMORS AND DRUG RESISTANCE | SEQUOIA PHARMACEUTICALS INC (US) | 2017-12-14 | — | — | US | disclosed |
| US-9820975-B2 | Compounds and methods for treating influenza | ROMARK LABORATORIES L.C. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9765359-B2 | Agents for improved delivery of nucleic acids to eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9604952-B2 | Compositions and methods for inhibiting cytochrome P450 2D6 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20170029448-A1 | POLYCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVEDDELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | MOLECULAR TRANSFER, INC. (US) | 2017-02-02 | — | — | US | disclosed |
| CN-106278965-A | Aryl alkyl asymmetric over cure compounds and synthetic method thereof and application | 华东师范大学 | 2017-01-04 | — | — | CN | disclosed |
| US-20160361287-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. | 2016-12-15 | — | — | US | disclosed |
| EP-3078377-A2 | NITAZOXANIDE AND TIZOXANIDE AS ANTI-VIRAL AGENTS | Romark Laboratories, L.C. (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20160271061-A1 | NANOPARTICLES AND NANOPARTICLE COMPOSITIONS | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2016-09-22 | — | — | US | disclosed |
| WO-2016138542-A1 | METHODS FOR INHIBITING TUMORS AND DRUG RESISTANCE | CYPRUS THERAPEUTICS, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| EP-3055030-A1 | AMPHOTERICIN B DERIVATIVES WITH IMPROVED THERAPEUTIC INDEX | The Board of Trustees of the University of Illinois (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20160228415-A1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | ROMARK LABORATORIES L.C. (US) | 2016-08-11 | — | — | US | disclosed |
| CN-105848721-A | Amphotericin B derivatives with improved therapeutic index | 伊利诺伊大学评议会 | 2016-08-10 | — | — | CN | disclosed |
| US-20160215012-A1 | AMPHOTERICIN B DERIVATIVES WITH IMPROVED THERAPEUTIC INDEX | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (IL) | 2016-07-28 | — | — | US | disclosed |
| EP-2178852-B9 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | ROMARK LAB LC (US) | 2016-06-22 | — | — | EP | disclosed |
| US-9345690-B2 | Compounds and methods for treating influenza | ROMARK LABORATORIES L.C. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160130607-A1 | AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | Molecular Transfer Inc. | 2016-05-12 | — | — | US | disclosed |
| US-9320713-B2 | Nanoparticles and nanoparticle compositions | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9259475-B2 | Agents for improved delivery of nucleic acids to eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9233952-B2 | Compositions and methods for inhibiting cytochrome P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150284352-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | SEQUOIA PHARMACEUTICALS INC (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150250768-A1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | ROMARK LABORATORIES L.C. (US) | 2015-09-10 | — | — | US | disclosed |
| US-9126992-B2 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES, L.C. (US) | 2015-09-08 | — | — | US | disclosed |
| EP-2912045-A2 | POLYCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | Molecular Transfer, Inc. (US) | 2015-09-02 | — | — | EP | disclosed |
| EP-2178852-B1 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | ROMARK LAB LC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-9023877-B2 | Compounds and methods for treating influenza | ROMARK LABORATORIES L.C. (US) | 2015-05-05 | — | — | US | disclosed |
| WO-2015054148-A1 | AMPHOTERICIN B DERIVATIVES WITH IMPROVED THERAPEUTIC INDEX | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-04-16 | — | — | WO | disclosed |
| US-8952056-B2 | Methods for inhibiting drug degradation | SEQUOIA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-8895752-B2 | Alkylsulfonyl-substituted thiazolide compounds | ROMARK LABORATORIES L.C. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140343078-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 2D6 | SEQUOIA PHARMACEUTICALS INC (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140341850-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | ROMARK LABORATORIES, L.C. (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140308360-A1 | NANOPARTICLES AND NANOPARTICLE COMPOSITIONS | NATIONAL SCIENCE FOUNDATION | 2014-10-16 | — | — | US | disclosed |
| EP-1940856-B1 | NOVEL UROKINASE INHIBITORS | UNIV ANTWERPEN (BE) | 2014-10-08 | — | — | EP | disclosed |
| US-8846727-B2 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES, L.C. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140213637-A1 | Agents for Improved Delivery of Nucleic Acids to Eukaryotic Cells | Molecular Transfer Inc. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8791157-B2 | 5-substituted benzofurans as inhibitors of cytochrome P450 2D6 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-8790621-B2 | Nanoparticles and nanoparticle compositions | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-8772502-B2 | Alkylsulfinyl-substituted thiazolide compounds | ROMARK LABORATORIES, L.C. (US) | 2014-07-08 | — | — | US | disclosed |
| WO-2014070687-A2 | POLYCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | MOLECULAR TRANSFER, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-8703700-B2 | Bimacrocylic HCV NS3 protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-2696678-A1 | AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | Molecular Transfer, Inc. (US) | 2014-02-19 | — | — | EP | disclosed |
| US-20140024671-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS INC (US) | 2014-01-23 | — | — | US | disclosed |
| EP-2134336-B1 | BENZOFURAN-DERIVED HIV PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS (US) | 2013-12-11 | — | — | EP | disclosed |
| US-8569364-B2 | 5-substituted benzofurans as inhibitors of cytochrome P450 2D6 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| WO-2013158127-A1 | AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | MOLECULAR TRANSFER, INC. (US) | 2013-10-24 | — | — | WO | disclosed |
| US-20130217704-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 2D6 | SEQUOIA PHARMACEUTICALS, INC. | 2013-08-22 | — | — | US | disclosed |
| US-8481520-B2 | Compositions and methods for inhibiting cytochrome P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20130101516-A1 | NANOPARTICLES AND NANOPARTICLE COMPOSITIONS | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| EP-2116538-B1 | CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| US-8389571-B2 | Benzofuran derived HIV protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20130045942-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2013-02-21 | — | — | US | disclosed |
| US-8367695-B2 | Condensed tetrahydroquinoline derivative and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-02-05 | — | — | US | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| WO-2012142622-A1 | AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | MOLECULAR TRANSFER, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
| EP-2511283-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES, N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2012-10-17 | — | — | EP | disclosed |
| US-20120237566-A1 | INHIBITING STOMACH-ACID RELEASE, REDUCING INFLAMMATION AND PREVENTING AND TREATING CANCER: COMPOSITIONS AND METHODS OF USE | Venture Isles, LLC (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120122939-A1 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | ROMARK LABORATORIES, L.C. | 2012-05-17 | — | — | US | disclosed |
| US-20120108591-A1 | ALKYLSULFINYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | ROMARK LABORATORIES, L.C. | 2012-05-03 | — | — | US | disclosed |
| US-20120108592-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES, L.C. | 2012-05-03 | — | — | US | disclosed |
| EP-2445349-A1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | Romark Laboratories, L.C. (US) | 2012-05-02 | — | — | EP | disclosed |
| EP-2432318-A1 | BIMACROCYCLIC HCV NS3 PROTEASE INHIBITORS | Sequoia Pharmaceuticals, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2429986-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | Romark Laboratories, L.C. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20120053132-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| EP-2422780-A1 | Resistance-repellent retroviral protease inhibitors | Sequoia Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-2422781-A1 | Resistance-repellent retroviral protease inhibitors | Sequoia Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-8124632-B2 | Alkylsulfonyl-substituted thiazolide compounds | ROMARK LABORATORIES, L.C. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20110312992-A1 | Inhibitors of C-Kit and Uses Thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2011-12-22 | — | — | US | disclosed |
| US-20110281824-A1 | BENZOFURAN DERIVED HIV PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| EP-1526862-B1 | SIMMONDSIN FOR USE AS AN ANGIOGENESIS INHIBITOR | OOSTERLYNCK ANDRE D (BE) | 2011-11-09 | — | — | EP | disclosed |
| US-8048871-B2 | Inhibitors that when coadministered with a drug that undergoes in vivo degradation by cytochrome P450 enzyme, improves the pharmacokinetics, bioavailability and disease treatment such as of HIV, Hepatitis C virus, diabetes, epilepsy, cancer, depression; amide or sulfonamide-functional benzofurans | SEQUOIA PHARMACEUTICALS, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-8003627-B2 | Urokinase inhibitors | UNIVERSITEIT ANTWERPEN (BE) | 2011-08-23 | — | — | US | disclosed |
| US-7981929-B2 | Resistance-repellent and multidrug resistant retroviral protease inhibitors; cytochrome P450 inhibitor | SEQUOIA PHARMACEUTICALS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981875-B2 | Treating pancreatic cancer by administering cardenolide uscharin extracted from Calotropis procera plants | UNIBIOSCREEN S.A. (BE) | 2011-07-19 | — | — | US | disclosed |
| US-20110098237-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | SEQUOIA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-7915253-B2 | 4-[2,6-Dimethyl-4-(4-trifluoromethoxy-phenyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid; peroxisome proliferator activated receptors modulator; antidiabetic, antiinflammatory agent; obesity, hyperinsulinemia, metabolic syndrome X, polycystic ovary syndrome, ischemia-associated organ injury | KALYPSYS, INC (US) | 2011-03-29 | — | — | US | disclosed |
| US-7906556-B2 | Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20110004019-A1 | Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same | SHISEIDO COMPANY LTD. (JP) | 2011-01-06 | — | — | US | disclosed |
| US-20100330173-A1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | ROMARK LABORATORIES L.C. | 2010-12-30 | — | — | US | disclosed |
| WO-2010151577-A1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | ROMARK LABORATORIES L.C. (US) | 2010-12-29 | — | — | WO | disclosed |
| US-7858642-B2 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| EP-2255780-A1 | PARAKERATOSIS INHIBITOR, PORE SHRINKING AGENT OR AGENT FOR PREVENTING OR IMPROVING ROUGH SKIN, AND COMPOSITION FOR EXTERNAL USE ON THE SKIN CONTAINING THE SAME | Shiseido Company, Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| EP-2254410-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | Sequoia Pharmaceuticals, Inc. (US) | 2010-12-01 | — | — | EP | disclosed |
| WO-2010135748-A1 | BIMACROCYCLIC HCV NS3 PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100292274-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | ROMARK LABORATORIES L.C. | 2010-11-18 | — | — | US | disclosed |
| WO-2010132404-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | ROMARK LABORATORIES L.C. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-7834004-B2 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | KALYPSYS, INC (US) | 2010-11-16 | — | — | US | disclosed |
| US-7829564-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2010-11-09 | — | — | US | disclosed |
| US-7825256-B2 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7807845-B2 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| EP-2224923-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 2D6 | Sequoia Pharmaceuticals, Inc. (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20100144738-A1 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-06-10 | — | — | US | disclosed |
| US-20100063055-A1 | CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100056596-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| US-20100009935-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS (US) | 2010-01-14 | — | — | US | disclosed |
| EP-2134336-A1 | BENZOFURAN-DERIVED HIV PROTEASE INHIBITORS | Sequoia Pharmaceuticals (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090281115-A1 | INHIBITORS OF C-KIT AND USES THEREOF | Board of Regents, The University of Texas System, a Texas University (US) | 2009-11-12 | — | — | US | disclosed |
| EP-2116538-A1 | CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090264417-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090227599-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| WO-2009105781-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | SEQUOIA PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | WO | disclosed |
| EP-1750696-A4 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS INC (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2009070744-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 2D6 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20090143408-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 2D6 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| EP-2061456-A2 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7531538-B2 | α- and β-Amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1732891-A4 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS INC (US) | 2009-05-06 | — | — | EP | disclosed |
| US-7517884-B2 | {5-[4-(4-Trifluoromethyl-phenyl)-piperazine-1-sulfonyl]-indan-2-yl}-acetic acid; peroxisome proliferator activated receptors modulator; antidiabetic, antiinflammatory agent; obesity, hyperinsulinemia, metabolic syndrome X, polycystic ovary syndrome, ischemia-associated organ injury, diabetes | KALYPSYS INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7507763-B2 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2009-03-24 | — | — | US | disclosed |
| WO-2009033505-A1 | HELLEBRIN DERIVATIVES | UNIBIOSCREEN S.A. (BE) | 2009-03-19 | — | — | WO | disclosed |
| US-7494999-B2 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | KALYPSYS, INC (US) | 2009-02-24 | — | — | US | disclosed |
| US-20090042961-A1 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090036467-A1 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | ROMARK LABORATORIES L.C. | 2009-02-05 | — | — | US | disclosed |
| US-20090029971-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090023664-A1 | ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE LLC (US) | 2009-01-22 | — | — | US | disclosed |
| US-20080312191-A1 | Novel Urokinase Inhibitors | UNIVERSITEIT ANTWERPEN (BE) | 2008-12-18 | — | — | US | disclosed |
| US-20080261935-A1 | 2\" OXO-VORUSCHARIN AND DERIVATIVES THEREOF | UNIBIOSCREEN S.A. (BE) | 2008-10-23 | — | — | US | disclosed |
| WO-2008115894-A1 | BENZOFURAN-DERIVED HIV PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080227744-A1 | BENZOFURAN DERIVED HIV PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| EP-1954694-A1 | IMIDAZOLE DERIVATIVES AS NITRIC OXIDE SYNTHASE DIMERISATION INHIBITOR | Kalypsys, Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1658846-B1 | N-(8,8,8-trifluorooctyl)-1,5-dideoxy-1,5-imino-D-glucitol for treating hepatitis virus infections | UNITED THERAPEUTICS CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080176842-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE LLC (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080166332-A1 | Methods of Treatment of Amyloidosis Using Subsituted Ethanolcyclicamine Aspartyl Protease Inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| EP-1940856-A1 | NOVEL UROKINASE INHIBITORS | Universiteit Antwerpen (BE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1941861-A1 | WRINKLE-IMPROVING AGENT | Shiseido Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| EP-1937638-A1 | METHODS OF TREATING AMYLOIDOSIS USING ARYL-CYCLOPROPYL DERIVATIVE ASPARTYL PROTEASE INHIBITORS | Elan Pharmaceuticals Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| US-7387999-B2 | Simmondsin for use as angiogenesis inhibitor | D'Oosterlynck, André (BE) | 2008-06-17 | — | — | US | disclosed |
| US-7385085-B2 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-7378441-B2 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-20080118969-A1 | BIS-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE LLC (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080113945-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080103311-A1 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| EP-1910342-A1 | MULTICYCLIC SULFONAMIDE COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008030744-A2 | INHIBITORS OF C-MET AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-03-13 | — | — | WO | disclosed |
| US-7339078-B2 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2008-03-04 | — | — | US | disclosed |
| WO-2008022345-A2 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
| EP-1709063-B1 | GLYCOSYLATED STEROID DERIVATIVES WITH ANTI-MIGRATORY ACTIVITY | UNIBIOSCREEN SA (BE) | 2008-01-23 | — | — | EP | disclosed |
| US-7320971-B2 | 2″ oxo-voruscharin and derivatives thereof | UNIBIOSCREEN S.A. (BE) | 2008-01-22 | — | — | US | disclosed |
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2008005877-A2 | INHIBITORS OF C-KIT AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-01-10 | — | — | WO | disclosed |
| EP-1871770-A1 | ORTHO-TERPHENYL INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | Kalypsys, Inc. (US) | 2008-01-02 | — | — | EP | disclosed |
| US-7312333-B2 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| US-7297793-B2 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE, LLC (US) | 2007-11-20 | — | — | US | disclosed |
| US-7285566-B2 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. | 2007-10-23 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20070197609-A1 | SALTS OF INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | KALYPSYS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070191371-A1 | HETEROCYCLIC MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| EP-1817030-A2 | INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | Kalypsys, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1805158-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | Kalypsys, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| EP-1802574-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ETHANOL CYCLICAMINE DERIVATIVES ASPARTYL PROTEASE INHIBITORS | Elan Pharmaceuticals Inc. (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20070149569-A1 | Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070149525-A1 | Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070149584-A9 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | JOHN VARGHESE | 2007-06-28 | — | — | US | disclosed |
| US-20070123473-A1 | Glycosylated steroid derivatives with anti-migratory activity | UNIBIOSCREEN S.A. (BE) | 2007-05-31 | — | — | US | disclosed |
| WO-2007062410-A1 | IMIDAZOLE DERIVATIVES AS NITRIC OXIDE SYNTHASE DIMERISATION INHIBITOR | KALYPSYS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-1789388-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING SUBSTITUTED ETHANOLCYCLICAMINE ASPARTYL PROTEASE INHIBITORS | Elan Pharmaceuticals, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2005087728-A9 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS INC (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045496-A1 | NOVEL UROKINASE INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047305-A1 | METHODS OF TREATING AMYLOIDOSIS USING CYCLOPROPYL DERIVATIVE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047306-A1 | METHODS OF TREATING AMYLOIDOSIS USING ARYL-CYCLOPROPYL DERIVATIVE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| EP-1773758-A1 | OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS | Elan Pharmaceuticals, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1773756-A2 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | Elan Pharmaceuticals, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-7199158-B2 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7192983-B2 | Improving storage stability by reacting with hydrogen sulfate lithium- containing compound; aspartyl protease inhibitors | G.D. SEARLE & CO. (US) | 2007-03-20 | — | — | US | disclosed |
| WO-2007025090-A2 | HETEROBICYCLIC AND - TRICYCLIC INHIBITORS OF MAPK/ERK KINASE | KALYPSYS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049591-A1 | Inhibitors of MAPK/Erk Kinase | KALYPSYS, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070037754-A1 | Inhibitors of HIV protease; 2S-[[(N-methylamino)acetyl]amino]-N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino)-1S-(phenylmethyl)propyl]-3,3-dimethyl-butanamide | G.D. SEARLE & CO. (US) | 2007-02-15 | — | — | US | disclosed |
| EP-1750696-A2 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2007015866-A2 | INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | KALYPSYS, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2007015877-A2 | INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | KALYPSYS, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007016354-A1 | MULTICYCLIC SULFONAMIDE COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027184-A1 | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. | 2007-02-01 | — | — | US | disclosed |
| WO-2007011760-A2 | INHIBITORS OF MITOTIC KINESIN | KALYPSYS, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007011759-A2 | INHIBITORS OF MITOTIC KINESIN | KALYPSYS, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007011647-A2 | INHIBITORS OF MITOTIC KINESIN KSP | KALYPSYS, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007011721-A1 | INHIBITORS OF MITOTIC KINESIN | KALYPSYS, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070015818-A1 | Cyclic sulfone containing retroviral protease inhibitors | G.D. Searle & Co. (now G.D. Searle, LLC) (US) | 2007-01-18 | — | — | US | disclosed |
| WO-2007008529-A2 | CELULLAR CHOLESTEROL ABSORPTION MODIFIERS | KALYPSYS, INC (US) | 2007-01-18 | — | — | WO | disclosed |
| US-7161033-B2 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2007-01-09 | — | — | US | disclosed |
| US-20070004646-A1 | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20060293286-A1 | Resistant-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2006-12-28 | — | — | US | disclosed |
| EP-1734961-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1735293-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1734942-A1 | SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1732891-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1730125-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1729755-A1 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20060276493-A1 | alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D SEARLE & CO. (US) | 2006-12-07 | — | — | US | disclosed |
| US-7141609-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-11-28 | — | — | US | disclosed |
| US-7141594-B2 | inhibitors of HIV protease for treating AIDS | G. D. SEARLE & CO. (US) | 2006-11-28 | — | — | US | disclosed |
| WO-2006124874-A2 | INHIBITORS OF B-RAF KINASE | KALYPSYS, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006124780-A2 | IH-BENZO [D] IMIDAZOLE COMPOUNDS AS INHIBITORS OF B-RAF KINASE | KALYPSYS, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060264483-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-11-23 | — | — | US | disclosed |
| US-20060264468-A1 | Use of substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections | UNITED THERAPEUTICS CORPORATION | 2006-11-23 | — | — | US | disclosed |
| US-20060258627-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2006-11-16 | — | — | US | disclosed |
| US-20060258737-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2006-11-16 | — | — | US | disclosed |
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
| WO-2006116355-A1 | ORTHO-TERPHENYL INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | KALYPSYS, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060241308-A1 | Probe for measuring phytase activity | BERRY & ASSOCIATES, INC. | 2006-10-26 | — | — | US | disclosed |
| US-20060241308-A1 | Probe for measuring phytase activity | BERRY & ASSOCIATES, INC. | 2006-10-26 | — | — | US | disclosed |
| WO-2006113140-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| EP-1709063-A2 | GLYCOSYLATED STEROID DERIVATIVES WITH ANTI-MIGRATORY ACTIVITY | Unibioscreen S.A. (BE) | 2006-10-11 | — | — | EP | disclosed |
| US-7115618-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20060217362-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | disclosed |
| US-7112683-B2 | Cyclic sulfone containing retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-09-26 | — | — | US | disclosed |
| US-7109230-B2 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060205736-A1 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | KALYPSYS, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060199822-A1 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-09-07 | — | — | US | disclosed |
| US-7098202-B2 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2006-08-29 | — | — | US | disclosed |
| US-20060189611-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-08-24 | — | — | US | disclosed |
| US-7091219-B2 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060166895-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (NOW NAMED PHARMACIA CORPORATION, WHICH IS A WHOLLY OWNED SUBSIDIARY OF PFIZER, INC (US) | 2006-07-27 | — | — | US | disclosed |
| US-20060167012-A1 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | KALYPSYS, INC. | 2006-07-27 | — | — | US | disclosed |
| US-20060166952-A1 | 2\"oxo-voruscharin and derivatives thereof | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2006-07-27 | — | — | US | disclosed |
| WO-2006071775-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-07-06 | — | — | WO | disclosed |
| US-20060149045-A1 | Steroid compounds with anti-tumor activity | UNIBIOSCREEN S.A. (BE) | 2006-07-06 | — | — | US | disclosed |
| US-7067670-B2 | Sulfamato hydroxamic acid metalloprotease inhibitor | WARNER LAMBERT COMPANY (US) | 2006-06-27 | — | — | US | disclosed |
| US-20060135581-A1 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-06-22 | — | — | US | disclosed |
| US-20060128715-A1 | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| WO-2006060424-A2 | INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | KALYPSYS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. | 2006-06-01 | — | — | US | disclosed |
| WO-2006055187-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| EP-1658846-A1 | Substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections | G.D. SEARLE & CO. (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1551850-B1 | 2\" OXO-VORUSCHARIN AND DERIVATIVES THEREOF | UNIBIOSCREEN SA (BE) | 2006-05-24 | — | — | EP | disclosed |
| US-7045518-B2 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-7037941-B2 | Alpha-and Beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2006-05-02 | — | — | US | disclosed |
| US-20060088613-A1 | Simmondsin for use as angiogenesis inhibitor | VAN DEN DRIESSCHE, HERMAN (BE) | 2006-04-27 | — | — | US | disclosed |
| US-20060084688-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | BARTA THOMAS E | 2006-04-20 | — | — | US | disclosed |
| US-7030161-B2 | α-and β-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-04-18 | — | — | US | disclosed |
| US-7026485-B2 | Retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-04-11 | — | — | US | disclosed |
| US-7026333-B1 | Retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20060074247-A1 | N-protected/N-substituted-beta-amino hydroxy sulfonates | G.D. SEARLE & CO. (US) | 2006-04-06 | — | — | US | disclosed |
| US-20060074098-A1 | Methods of treatment of amyloidosis using ethanolcyclicamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-04-06 | — | — | US | disclosed |
| WO-2006026532-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING SUBSTITUTED ETHANOLCYCLICAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006026533-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ETHANOL CYCLICAMINE DERIVATIVES ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20060040974-A1 | Retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-02-23 | — | — | US | disclosed |
| WO-2006010094-A1 | OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060020009-A1 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-01-26 | — | — | US | disclosed |
| WO-2006010095-A2 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060014737-A1 | Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | disclosed |
| US-20060014790-A1 | Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | disclosed |
| EP-1616874-A1 | Mono- and bicyclic compounds with therapeutic activity and pharmaceutical compositions including them | UNIVERSITEIT GENT (BE) | 2006-01-18 | — | — | EP | disclosed |
| US-20050267171-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2005-12-01 | — | — | US | disclosed |
| US-20050267074-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2005-12-01 | — | — | US | disclosed |
| WO-2005110428-A2 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050261273-A1 | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050227926-A1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2005-10-13 | — | — | US | disclosed |
| WO-2005087714-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050209301-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2005-09-22 | — | — | US | disclosed |
| WO-2005087215-A1 | SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087728-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087751-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087752-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| EP-1572715-A1 | STEROID COMPOUNDS WITH ANTI-TUMOR ACTIVITY | Unibioscreen S.A. (BE) | 2005-09-14 | — | — | EP | disclosed |
| EP-0813543-B1 | BIS-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | SEARLE LLC (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005070407-A1 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-6924286-B1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2005-08-02 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1551850-A1 | 2\" OXO-VORUSCHARIN AND DERIVATIVES THEREOF | Unibioscreen S.A. (BE) | 2005-07-13 | — | — | EP | disclosed |
| WO-2005058934-A2 | GLYCOSYLATED STEROID DERIVATIVES WITH ANTI-MIGRATORY ACTIVITY | UNIBIOSCREEN S.A. (BE) | 2005-06-30 | — | — | WO | disclosed |
| EP-1483254-A4 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20050119257-A1 | cyclic thiophene or thiopyran sulfone- and either urea- or N-heterocyclic moiety-containing hydroxyethylamine; mimetic compound binds to the enzyme; HIV virus | G.D. SEARLE & CO. (US) | 2005-06-02 | — | — | US | disclosed |
| US-20050119338-A1 | Combination of cytochome p450 dependent protease inhibitors | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-06-02 | — | — | US | disclosed |
| EP-0813867-B1 | Retroviral protease inhibitors | MONSANTO CO (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050107342-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| US-6890937-B2 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1526862-A1 | SIMMONDSIN FOR USE AS AN ANGIOGENESIS INHIBITOR | d'Oosterlynck, André (BE) | 2005-05-04 | — | — | EP | disclosed |
| US-6875790-B2 | Cyclic sulfone containing retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2005-04-05 | — | — | US | disclosed |
| US-20050049280-A1 | Sulfamato hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2005-03-03 | — | — | US | disclosed |
| US-6861539-B1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2005-03-01 | — | — | US | disclosed |
| EP-0983267-B1 | AMIDOAROMATIC RING SULFONAMIDE HYDROXAMIC ACID COMPOUNDS | PHARMACIA CORP (US) | 2005-01-26 | — | — | EP | disclosed |
| US-6846954-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2005-01-25 | — | — | US | disclosed |
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | PHARMACIA CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-20050004230-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (NOW NAMED PHARMACIA CORPORATION, WHICH IS A WHOLLY OWNED SUBSIDIARY OF PFIZER, INC (US) | 2005-01-06 | — | — | US | disclosed |
| US-20040260095-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2004-12-23 | — | — | US | disclosed |
| EP-1483254-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | Sequoia Pharmaceuticals (US) | 2004-12-08 | — | — | EP | disclosed |
| EP-0977745-B1 | THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS | PHARMACIA CORP (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040235818-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2004-11-25 | — | — | US | disclosed |
| US-20040229922-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2004-11-18 | — | — | US | disclosed |
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20040198989-A1 | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2004-10-07 | — | — | US | disclosed |
| US-6800646-B1 | Sulfamato hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2004-10-05 | — | — | US | disclosed |
| US-20040186151-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-23 | — | — | US | disclosed |
| EP-1458447-A2 | COMBINATION OF CYTOCHOME P 450 DEPENDENT PROTEASE INHIBITORS | Tibotec Pharmaceuticals Ltd. (IE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004076433-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | AIC (BE) | 2004-09-10 | — | — | WO | disclosed |
| US-20040171653-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2004-09-02 | — | — | US | disclosed |
| WO-2004071448-A2 | SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | TRANSTECH PHARMA INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| EP-1447398-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20040147758-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2004-07-29 | — | — | US | disclosed |
| EP-1052250-B1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | SEARLE & CO (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6762187-B2 | HETEROCYCLIC NITROGEN COMPOUNDS USED AS ENZYME INHIBITORS FOR PROPHYLAXIS OF HUMAN IMMUNODEFICIENCY VIRUS(HIV) | MONSANTO COMPANY | 2004-07-13 | — | — | US | disclosed |
| WO-2004055039-A1 | STEROID COMPOUNDS WITH ANTI-TUMOR ACTIVITY | UNIBIOSCREEN S.A. (BE) | 2004-07-01 | — | — | WO | disclosed |
| US-20040127539-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
| US-6750233-B2 | SELECTIVITY | PHARMACIA CORPORATION | 2004-06-15 | — | — | US | disclosed |
| US-6747149-B2 | ADMINISTERING VIRICIDES SUCH AS N-NONENYL GLUCOSAMINE, AND OPTIONALLY WITH MIXTURES OF NUCLEOSIDES, NUCLEOTIDES, IMMUNOMODULATORS OR IMMUNOSTIMULANTS FOR PROPHYLAXIS VIRAL DISEASES | G. D. SEARLE & CO. | 2004-06-08 | — | — | US | disclosed |
| US-6747027-B1 | SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 | PHARMACIA CORPORATION | 2004-06-08 | — | — | US | disclosed |
| EP-1414526-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Pharmacia Corporation (US) | 2004-05-06 | — | — | EP | disclosed |
| US-6730669-B2 | PROPHYLACTICALLY PREVENTING RETROVIRAL INFECTION OR THE SPREAD OF A RETROVIRUS, AND TREATMENT OF A RETROVIRAL INFECTION | G. D. SEARLE & CO. | 2004-05-04 | — | — | US | disclosed |
| WO-2004033465-A1 | 2' OXO-VORUSCHARIN AND DERIVATIVES THEREOF | UNIBIOSCREEN S.A. (BE) | 2004-04-22 | — | — | WO | disclosed |
| EP-1408043-A1 | 2''oxo-voruscharin and analogues thereof | Unibioscreen S.A. (BE) | 2004-04-14 | — | — | EP | disclosed |
| US-20040063771-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2004-04-01 | — | — | US | disclosed |
| US-20040048852-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2004-03-11 | — | — | US | disclosed |
| US-20040044047-A1 | Alpha and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2004-03-04 | — | — | US | disclosed |
| US-20040034071-A1 | Thioaryl sulfonamide hydroxamic acid compounds | PHARMACIA CORPORATION | 2004-02-19 | — | — | US | disclosed |
| US-6683210-B2 | HUMAN T-CELL LEUKEMIA/LYMPHOMA VIRUS, HUMAN IMMUNODEFICIENCY VIRUS, AND LYMPHADENOPATHY ASSOCIATED VIRUS TREATMENT | G. D. SEARLE & CO. | 2004-01-27 | — | — | US | disclosed |
| WO-2004004746-A1 | SIMMONDSIN FOR USE AS AN ANGIOGENESIS INHIBITOR | D OOSTERLYNCK ANDRE (BE) | 2004-01-15 | — | — | WO | disclosed |
| US-20040010143-A1 | Cyclic sulfone containing retroviral protease inhibitors | G.D. SEARLE & CO. | 2004-01-15 | — | — | US | disclosed |
| US-6673822-B2 | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. | 2004-01-06 | — | — | US | disclosed |
| US-6667307-B2 | HIV protease | G.D. SEARLE & CO. | 2003-12-23 | — | — | US | disclosed |
| US-20030220508-A1 | Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inyhibitors | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | disclosed |
| US-20030220299-A1 | Especially treating hepatitis B and hepatitis C; may be used alone, or in combination with another antiviral agent such as nucleosides, nucleotides, immunomodulators, and/or immunostimulants | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | disclosed |
| US-20030216435-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. | 2003-11-20 | — | — | US | disclosed |
| US-20030204097-A1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2003-10-30 | — | — | US | disclosed |
| US-20030195227-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 2003-10-16 | — | — | US | disclosed |
| US-20030195229-A1 | Glucamine salts for treating hepatitis virus infections | PHARMACIA CORPORATION | 2003-10-16 | — | — | US | disclosed |
| US-20030191166-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2003-10-09 | — | — | US | disclosed |
| US-20030171423-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. | 2003-09-11 | — | — | US | disclosed |
| US-20030158236-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2003-08-21 | — | — | US | disclosed |
| WO-2003064406-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS (US) | 2003-08-07 | — | — | WO | disclosed |
| US-20030130202-A1 | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. | 2003-07-10 | — | — | US | disclosed |
| US-6586627-B1 | Blocking carbocyclic oxo, amines such as 2-(bis(phenylmethyl) amino)-3-phenylpropanal to form 2-(Bis(phenylmethyl)amino)-1-hydroxy-3-phenylpropylsulfonic Acid Salts, having storage stability; chemical intermediates for enzyme inhibitors | G. D. SEARLE & CO. | 2003-07-01 | — | — | US | disclosed |
| US-6583299-B1 | Matrix metalloprotease inhibitors; nonsuppression of tumor necrosis factor production | G.D. SEARLE & CO. | 2003-06-24 | — | — | US | disclosed |
| WO-2003049746-A2 | COMBINATION OF CYTOCHOME P450 DEPENDENT PROTEASE INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2003-06-19 | — | — | WO | disclosed |
| US-6569882-B2 | Viricides; enzyme inhibitors | G. D. SEARLE & CO. | 2003-05-27 | — | — | US | disclosed |
| US-20030087942-A1 | Method for the treatment and prevention of cachexia | WASHINGTON UNIVERSITY | 2003-05-08 | — | — | US | disclosed |
| US-6552203-B2 | Optionally oxygenated hydrogenated thiophenes, thiopyrans and thiomorpholines containing hydroxyethylamine groups | MONSANTO COMPANY | 2003-04-22 | — | — | US | disclosed |
| US-6545021-B1 | Including ether and ester derivatives as well as N-carbonyl derivatives | G.D. SEARLE & CO. | 2003-04-08 | — | — | US | disclosed |
| US-6541489-B1 | Excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP- 1 | G. D. SEARLE & COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-6538006-B1 | N-heterocyclic moiety-containing hydroxyethylamine protease inhibitor compounds, methods for making the compounds, and intermediates useful in the method. Also, a method for inhibiting retroviral proteases and for treatment of | PHARMACIA CORPORATION | 2003-03-25 | — | — | US | disclosed |
| WO-2003020268-A1 | METHOD FOR THE TREATMENT AND PREVENTION OF CACHEXIA | WASHINGTON UNIVERSITY (US) | 2003-03-13 | — | — | WO | disclosed |
| EP-0939628-B1 | THIOL SULFONE METALLOPROTEASE INHIBITORS | MONSANTO CO (US) | 2003-03-05 | — | — | EP | disclosed |
| US-6515024-B2 | For therapy of retroviral infection, e.g., an HIV infection | G. D. SEARLE & CO. | 2003-02-04 | — | — | US | disclosed |
| US-6515028-B1 | Used alone, or in combination with another antiviral agents selected from among nucleosides, nucleotides, immunomodulators, immunostimulants or various combinations of such other agents | G.D. SEARLE & CO. | 2003-02-04 | — | — | US | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| US-6506759-B1 | Method for treating HIV-related AIDS comprising administering an effective amount of a composition N-heterocyclic moiety containing hydroxyethylamine compounds are effective as retroviral protease inhibitors, and in | MONSANTO COMPANY | 2003-01-14 | — | — | US | disclosed |
| US-6492367-B1 | Sulfamato hydroxamic acid metalloprotease inhibitor | G. D. SEARLE & COMPANY | 2002-12-10 | — | — | US | disclosed |
| EP-0815124-B1 | HETEROCYCLECARBONYL AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 2002-12-04 | — | — | EP | disclosed |
| US-20020177588-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2002-11-28 | — | — | US | disclosed |
| EP-1258491-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2002-11-20 | — | — | EP | disclosed |
| EP-1255748-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| US-6468977-B1 | COMPOUNDS USEFUL IN TREATMENT TREATMENT OF DISORDER AND/OR DISEASE CAUSED BY ACTIVITY OF ENZYMES SUCH AS HUMAN RHINOVIRUS 3C PROTEASE, TRANSGLUTAMINASE AND CATHEPSINS | APOTEX INC. (CA) | 2002-10-22 | — | — | US | disclosed |
| EP-0813542-B1 | AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 2002-10-16 | — | — | EP | disclosed |
| US-6458785-B1 | AIDS THERAPY | G. D. SEARLE | 2002-10-01 | — | — | US | disclosed |
| US-20020137942-A1 | Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | VAZQUEZ MICHAEL L (US) | 2002-09-26 | — | — | US | disclosed |
| US-6451791-B1 | Amidoaromatic ring sulfonamide hydroxamic acid compounds | MONSANTO COMPANY | 2002-09-17 | — | — | US | disclosed |
| US-6448250-B1 | INHIBITS THE ACTIVITY OF ONE OR MORE OF THE FOLLOWING MATRIX METALLOPROTEINASES: MMP-2, MMP-9, AND MMP-13, WHILE EXHIBITING SUBSTANTIALLY LESS INHIBITORY ACTIVITY AGAINST MMP-1 | G. D. SEARLE & COMPANY | 2002-09-10 | — | — | US | disclosed |
| US-6444678-B1 | α- and β-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors | G. D. SEARLE & CO. | 2002-09-03 | — | — | US | disclosed |
| US-20020111368-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | GETMAN DANIEL P (US) | 2002-08-15 | — | — | US | disclosed |
| EP-1230219-A1 | AROMATIC SULFONS HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. Searle & Co. (US) | 2002-08-14 | — | — | EP | disclosed |
| US-20020107264-A1 | Cyclic sulfone containing retroviral protease inhibitors | BERTENSHAW DEBORAH E (US) | 2002-08-08 | — | — | US | disclosed |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2002-08-01 | — | — | US | disclosed |
| EP-0939629-A4 | THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS | MONSANTO CO (US) | 2002-07-17 | — | — | EP | disclosed |
| US-6417387-B1 | IN PARTICULAR AS INHIBITORS OF HIV PROTEASE. | G.D. SEARLE & CO. | 2002-07-09 | — | — | US | disclosed |
| US-6407134-B1 | VIRICIDE FOR HUMAN T-CELL LEUKEMIA/LYMPHOMA VIRUS | G. D. SEARLE & CO. | 2002-06-18 | — | — | US | disclosed |
| EP-0810209-B1 | Alpha - and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | SEARLE & CO (US) | 2002-06-05 | — | — | EP | disclosed |
| EP-0883622-B1 | PROTON PUMP INHIBITOR | APOTEX INC (CA) | 2002-05-15 | — | — | EP | disclosed |
| US-6388132-B1 | AIDS THERAPY | G. D. SEARLE & CO. | 2002-05-14 | — | — | US | disclosed |
| US-6384036-B1 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE & CO. | 2002-05-07 | — | — | US | disclosed |
| US-20020052399-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | VAZQUEZ MICHAEL L (US) | 2002-05-02 | — | — | US | disclosed |
| US-6380188-B1 | FOR INHIBITING HUMAN IMMUNODEFICIENCY VIRUS PROTEASE | G. D. SEARLE & CO. | 2002-04-30 | — | — | US | disclosed |
| EP-1188766-A1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. Searle & Co. (US) | 2002-03-20 | — | — | EP | disclosed |
| EP-1183239-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2002-03-06 | — | — | EP | disclosed |
| EP-1173161-A2 | GLUCAMINE COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 2002-01-23 | — | — | EP | disclosed |
| EP-1165080-A2 | USE OF SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 2002-01-02 | — | — | EP | disclosed |
| US-6335460-B1 | TREATING RETROVIRAL INFECTIONS, INCLUDING HUMAN IMMUNODEFICIENCY VIRUS, AND AIDS | G.D. SEARLE & CO. | 2002-01-01 | — | — | US | disclosed |
| US-6329524-B1 | AS AN INHIBITOR OF HIV (HUMAN IMMUNODEFICIENCY VIRUS) PROTEASE | MONSANTO COMPANY | 2001-12-11 | — | — | US | disclosed |
| WO-2001090095-A1 | THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF CYSTEINE ACTIVITY DEPENDENT ENZYMES | APOTEX INC. (CA) | 2001-11-29 | — | — | WO | disclosed |
| EP-1157021-A1 | SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6316496-B1 | FOR THERAPY OF RETROVIRAL INFECTION; PROPHYLAXIS OF REPLICATION OF RETROVIRUS, THERAPY OF AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | G. D. SEARLE & CO. | 2001-11-13 | — | — | US | disclosed |
| US-20010039287-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | PHARMACIA CORPORATION | 2001-11-08 | — | — | US | disclosed |
| US-6313345-B1 | AIDS TREATMENT | G. D. SEARLE & CO. | 2001-11-06 | — | — | US | disclosed |
| US-6310080-B1 | TREATING RETROVIRAL INFECTIONS SUCH AS AIDS | G. D. SEARLE & CO. | 2001-10-30 | — | — | US | disclosed |
| EP-1148050-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2001060813-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
| US-20010014688-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | BARTA THOMAS E (US) | 2001-08-16 | — | — | US | disclosed |
| US-6265583-B1 | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | G. D. SEARLE & CO. | 2001-07-24 | — | — | US | disclosed |
| EP-0813519-B1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 2001-05-09 | — | — | EP | disclosed |
| EP-1095022-A1 | RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 2001-05-02 | — | — | EP | disclosed |
| US-6214861-B1 | ENZYME INHIBITOR; VIRICIDES | G.D. SEARLE & CO. | 2001-04-10 | — | — | US | disclosed |
| EP-0641325-B1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO CO (US) | 2001-03-07 | — | — | EP | disclosed |
| EP-1076062-A1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2001-02-14 | — | — | EP | disclosed |
| WO-2001008672-A2 | GLUCAMINE COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 2001-02-08 | — | — | WO | disclosed |
| US-6180646-B1 | PREVENT REPRODUCTION OF RETROVIRUS | MONSANTO COMPANY | 2001-01-30 | — | — | US | disclosed |
| US-6172082-B1 | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | G. D. SEARLE & CO. | 2001-01-09 | — | — | US | disclosed |
| US-6172101-B1 | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | G. D. SEARLE & CO. | 2001-01-09 | — | — | US | disclosed |
| US-6169085-B1 | A VIRICIDE FOR PREVENTING AND TREATING RETROVIRAL INFECTION OR THE SPREAD OF A RETROVIRUS, INHIBITING REPLICATION OF A RETROVIRUS AND TREATING AIDS | G. D. SEARLE & COMPANY | 2001-01-02 | — | — | US | disclosed |
| US-6162791-A | Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes | APOTEX INC. (CA) | 2000-12-19 | — | — | US | disclosed |
| EP-1058690-A1 | THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF CYSTEINE ACTIVITY DEPENDENT ENZYMES | APOTEX INC. (CA) | 2000-12-13 | — | — | EP | disclosed |
| WO-2000069821-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-11-23 | — | — | WO | disclosed |
| US-6150556-A | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS(HIV) PROTEASE; PROPHYLAXIS AND THERAPY OF RETROVIRUS INFECTIONS | G. D. DEARLE & CO. (US) | 2000-11-21 | — | — | US | disclosed |
| EP-1052250-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2000-11-15 | — | — | EP | disclosed |
| US-6147253-A | STABILIZED FORM OF N-PROTECTED/N-SUBSTITUTED ALPHA-AMINO ALDEHYDES | G. D. SEARLE & CO. (US) | 2000-11-14 | — | — | US | disclosed |
| US-6143788-A | ENZYME INHIBITORS | G.D. SEARLE & CO. (US) | 2000-11-07 | — | — | US | disclosed |
| US-6143747-A | ENZYME INHIBITORS | G. D. SEARLE & CO. (US) | 2000-11-07 | — | — | US | disclosed |
| US-6140505-A | REACTING A BENZO FUSED HETEROCYCLIC COMPOUND WITH AN SO3 COMPLEX IN THE PRESENCE OF A WATER IMMISCIBLE, NON-REACTIVE SOLVENT, AT A TEMPERATURE OF FROM ABOUT 0 TO ABOUT 75 DEGREES C., COOLING AND THEN ADDING OXALYL HALIDE. | G. D. SEARLE & CO. (US) | 2000-10-31 | — | — | US | disclosed |
| EP-1042290-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-0731088-B1 | Retroviral protease inhibitors | MONSANTO CO (US) | 2000-10-04 | — | — | EP | disclosed |
| EP-0735019-B1 | Retroviral protease inhibitors | MONSANTO CO (US) | 2000-09-20 | — | — | EP | disclosed |
| US-6114537-A | 1,2,4-THIADIAZOLE COMPOUND IS USEFUL FOR TRAPPING THIOL COMPOUNDS AND SELECTIVELY CHANGING THIOLS TO DISULFIDE COMPOUNDS | APOTEX INC. (CA) | 2000-09-05 | — | — | US | disclosed |
| WO-2000050396-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-2000047198-A2 | USE OF SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000046221-A1 | SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-08-10 | — | — | WO | disclosed |
| US-6093738-A | IMIDAZO(1,2-D)-THIADIAZOLE COMPOUNDS; PEPTIC ULCER TREATMENT | KARIMIAN KHASHAYAR (CA) | 2000-07-25 | — | — | US | disclosed |
| US-6087359-A | A MATRIX METALLOPROTEASE ENZYME INHIBITOR | PHARMACIA CORPORATION | 2000-07-11 | — | — | US | disclosed |
| US-6063795-A | ENZYME INHIBITORS | G.D. SEARLE & COMPANY (US) | 2000-05-16 | — | — | US | disclosed |
| US-6060472-A | Thiadiazole compounds useful as inhibitors of H+ /K+ atpase | APOTEX INC. (CA) | 2000-05-09 | — | — | US | disclosed |
| EP-0861233-B1 | N-PROTECTED/N-SUBSTITUTED-BETA-AMINO HYDROXY SULFONATES | SEARLE & CO (US) | 2000-05-03 | — | — | EP | disclosed |
| EP-0989982-A1 | BARBITURIC ACID DERIVATIVES WITH ANTIMETASTATIC AND ANTITUMOR ACTIVITY | Roche Diagnostics GmbH (DE) | 2000-04-05 | — | — | EP | disclosed |
| EP-0983267-A1 | AMIDOAROMATIC RING SULFONAMIDE HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 2000-03-08 | — | — | EP | disclosed |
| EP-0977745-A1 | THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-2000002862-A1 | RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-01-20 | — | — | WO | disclosed |
| US-6013649-A | BOND DISORDERS; AUTOIMMUNE DISEASES; ANTITUMOR AGENTS | MONSANTO COMPANY (US) | 2000-01-11 | — | — | US | disclosed |
| EP-0939628-A4 | THIOL SULFONE METALLOPROTEASE INHIBITORS | MONSANTO CO (US) | 1999-12-22 | — | — | EP | disclosed |
| WO-1999059989-A1 | PROCESS FOR THE PREPARATION OF A BENZO FUSED HETEROCYCLO SULFONYL HALIDE INTERMEDIATE | G.D. SEARLE & CO. (US) | 1999-11-25 | — | — | WO | disclosed |
| EP-0957093-A2 | Retrovial protease inhibitors | MONSANTO COMPANY (US) | 1999-11-17 | — | — | EP | disclosed |
| US-5985870-A | TREATING HIV INFECTIONS | G.D. SEARLE & CO. (US) | 1999-11-16 | — | — | US | disclosed |
| US-5972989-A | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1999-10-26 | — | — | US | disclosed |
| US-5968970-A | TREATMENT OF HIV | G. D. SEARLE & COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| WO-1999051584-A1 | THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF H+/K+ ATPASE | APOTEX INC. (CA) | 1999-10-14 | — | — | WO | disclosed |
| US-5965601-A | NOVEL COMPOUNDS FOR INHIBITING REPLICATION OF A RETROVIRUS; TREATING HIV | G. D. SEARLE & CO. (US) | 1999-10-12 | — | — | US | disclosed |
| WO-1999045027-A1 | THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF CYSTEINE ACTIVITY DEPENDENT ENZYMES | APOTEX INC. (CA) | 1999-09-10 | — | — | WO | disclosed |
| EP-0939629-A1 | THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1999-09-08 | — | — | EP | disclosed |
| EP-0939628-A1 | THIOL SULFONE METALLOPROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1999-09-08 | — | — | EP | disclosed |
| US-5948790-A | VIRICIDES | MOSANTO COMPANY (US) | 1999-09-07 | — | — | US | disclosed |
| US-5939587-A | DEBLOCKING, DESALTING, DESULFONATING AND OXIDATING TO ALDEHYDE; STORAGE STABILITY, MATERIALS HANDLING | G. D. SEARLE & COMPANY (US) | 1999-08-17 | — | — | US | disclosed |
| WO-1999025687-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 1999-05-27 | — | — | WO | disclosed |
| CN-1216527-A | Method for scavenging mercaptan | APOTEX INC (CA) | 1999-05-12 | — | — | CN | disclosed |
| WO-1998058925-A1 | BARBITURIC ACID DERIVATIVES WITH ANTIMETASTATIC AND ANTITUMOR ACTIVITY | ROCHE DIAGNOSTICS GMBH (DE) | 1998-12-30 | — | — | WO | disclosed |
| EP-0715618-B1 | HYDROXYETHYLAMINO SULPHONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 1998-12-16 | — | — | EP | disclosed |
| EP-0883622-A1 | PROTON PUMP INHIBITOR | APOTEX INC. (CA) | 1998-12-16 | — | — | EP | disclosed |
| EP-0883606-A1 | PROCESS FOR SCAVENGING THIOLS | APOTEX INC. (CA) | 1998-12-16 | — | — | EP | disclosed |
| US-5849784-A | Cyclic sulfone containing retroviral protease inhibitors | GD SEARLE & CO. (US) | 1998-12-15 | — | — | US | disclosed |
| US-5846941-A | Isosteric antiherpes peptide derivatives II | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1998-12-08 | — | — | US | disclosed |
| US-5847201-A | N-protected/N-substituted-beta-amino hydroxy sulfonates | G.D. SEARLE & CO. (US) | 1998-12-08 | — | — | US | disclosed |
| US-5830888-A | Macrocyclic retroviral protease inhibitors | MONSANTO COMPANY (US) | 1998-11-03 | — | — | US | disclosed |
| EP-0656887-B1 | HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 1998-10-28 | — | — | EP | disclosed |
| WO-1998039313-A1 | THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 1998-09-11 | — | — | WO | disclosed |
| WO-1998039329-A1 | AMIDOAROMATIC RING SULFONAMIDE HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 1998-09-11 | — | — | WO | disclosed |
| EP-0861249-A1 | SUBSTITUTED SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-09-02 | — | — | EP | disclosed |
| EP-0861233-A1 | N-PROTECTED/N-SUBSTITUTED-BETA-AMINO HYDROXY SULFONATES | G.D. SEARLE & CO. (US) | 1998-09-02 | — | — | EP | disclosed |
| EP-0560267-B1 | Isosteric antiherpes peptide derivatives | BOEHRINGER INGELHEIM CA LTD (CA) | 1998-08-19 | — | — | EP | disclosed |
| US-5776971-A | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5756534-A | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 1998-05-26 | — | — | US | disclosed |
| US-5756533-A | ENZYME INHIBITORS FOR TREATMENT OF AIDS | G.D. SEARLE & CO. (US) | 1998-05-26 | — | — | US | disclosed |
| US-5753660-A | Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1998-05-19 | — | — | US | disclosed |
| US-5753670-A | ANTICOAGULANTS | THE GREEN CROSS CORPORATION (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5744481-A | β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1998-04-28 | — | — | US | disclosed |
| WO-1998003164-A1 | THIOL SULFONE METALLOPROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1998-01-29 | — | — | WO | disclosed |
| WO-1998003166-A1 | THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1998-01-29 | — | — | WO | disclosed |
| US-5708004-A | ENZYME INHIBITORS FOR TREATMENT OF AIDS | MONSANTO COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| EP-0656888-B1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 1998-01-07 | — | — | EP | disclosed |
| EP-0815124-A1 | HETEROCYCLECARBONYL AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-01-07 | — | — | EP | disclosed |
| US-5705500-A | HIV TREATMENT | G.D. SEARLE & CO. (US) | 1998-01-06 | — | — | US | disclosed |
| EP-0813519-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-12-29 | — | — | EP | disclosed |
| EP-0813543-A1 | BIS-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-12-29 | — | — | EP | disclosed |
| US-5698569-A | Retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1997-12-16 | — | — | US | disclosed |
| EP-0810209-A2 | Alpha - and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1997-12-03 | — | — | EP | disclosed |
| EP-0804428-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5677302-A | Thiadiazole compounds useful as proton pump inhibitors | APOTEX INC. (CA) | 1997-10-14 | — | — | US | disclosed |
| WO-1997031923-A1 | PROTON PUMP INHIBITOR | APOTEX INC. (CA) | 1997-09-04 | — | — | WO | disclosed |
| WO-1997031893-A1 | PROCESS FOR SCAVENGING THIOLS | APOTEX INC. (CA) | 1997-09-04 | — | — | WO | disclosed |
| US-5652369-A | PROTEASE INHIBITOR | HOFFMANN-LA ROCHE INC. (US) | 1997-07-29 | — | — | US | disclosed |
| US-5648364-A | HETEROCYCLIC PEPTIDE COMPOUNDS AS ENZYME INHIBITORS | MONSANTO COMPANY (US) | 1997-07-15 | — | — | US | disclosed |
| US-5643924-A | Retroviral protease inhibitors | MONSANTO COMPANY OF ST. LOUIS (US) | 1997-07-01 | — | — | US | disclosed |
| US-5635527-A | ANTAGONIST OF PLATELET MEMBRANE GLYCOPROTEIN; TREATMENT OF THROMBOTIC DISEASES | THE GREEN CROSS CORPORATION (JP) | 1997-06-03 | — | — | US | disclosed |
| WO-1997018205-A1 | SUBSTITUTED SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-05-22 | — | — | WO | disclosed |
| WO-1997018190-A1 | N-PROTECTED/N-SUBSTITUTED-BETA-AMINO HYDROXY SULFONATES | G.D. SEARLE & CO. (US) | 1997-05-22 | — | — | WO | disclosed |
| US-5622949-A | AIDS THERAPY | G. D. SEARLE & CO. (US) | 1997-04-22 | — | — | US | disclosed |
| EP-0767671-A1 | METHOD OF COMBATING ACYCLOVIR-RESISTANT HERPES SIMPLEX VIRAL INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1997-04-16 | — | — | EP | disclosed |
| US-5620977-A | HUMAN IMMUNODEFICIENCY VIRUS | G.D. SEARLE & CO. (US) | 1997-04-15 | — | — | US | disclosed |
| US-5620987-A | Amino acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 1997-04-15 | — | — | US | disclosed |
| US-5614522-A | SULFONAMIDE AND UREA-CONTAINING HYDROXYETHYLAMINE COMPOUNDS | G.D. SEARLE & CO. (US) | 1997-03-25 | — | — | US | disclosed |
| US-5610190-A | Retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1997-03-11 | — | — | US | disclosed |
| US-5602175-A | HYDROXYETHYLAMINE COMPOUNDS; USEFUL IN TREATMENT OF INFECTIONS CAUSED BY THE HUMAN IMMUNODEFICIENCY VIRUS | G.D. SEARLE & CO. (US) | 1997-02-11 | — | — | US | disclosed |
| EP-0677048-B1 | CYCLIC SULFONE CONTAINING RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 1997-01-22 | — | — | EP | disclosed |
| US-5583248-A | Amino acid derivatives having antiviral activity | HOFFMANN-LA ROCHE INC. (US) | 1996-12-10 | — | — | US | disclosed |
| US-5580999-A | Alcohols | HOFFMANN-LA ROCHE INC. (US) | 1996-12-03 | — | — | US | disclosed |
| EP-0741696-A1 | MALARIAL ASPARTIC PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-11-13 | — | — | EP | disclosed |
| US-5574015-A | Isosteric antiherpes peptide derivatives | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1996-11-12 | — | — | US | disclosed |
| US-5571920-A | Alcohols | HOFFMANN-LA ROCHE INC. (US) | 1996-11-05 | — | — | US | disclosed |
| WO-1996028464-A1 | BIS-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |
| WO-1996028418-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |
| WO-1996028465-A1 | HETEROCYCLECARBONYL AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |
| WO-1996028463-A1 | AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |
| CN-1131418-A | Novel fused-ring carboxylic acid compound or salt thereof, and medicinal use thereof | GREEN CROSS CORP (JP) | 1996-09-18 | — | — | CN | disclosed |
| US-5554756-A | PROTEASE INHIBITOR | HOFFMANN-LA ROCHE INC. (US) | 1996-09-10 | — | — | US | disclosed |
| WO-1996022287-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-07-25 | — | — | WO | disclosed |
| EP-0715618-A1 | HYDROXYETHYLAMINO SULPHONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-06-12 | — | — | EP | disclosed |
| EP-0432694-B1 | Aminoalcohols | HOFFMANN LA ROCHE (CH) | 1996-05-29 | — | — | EP | disclosed |
| US-5521219-A | TREATMENT OF AIDS | G. D. SEARLE & CO. (US) | 1996-05-28 | — | — | US | disclosed |
| EP-0712844-A1 | NOVEL FUSED-RING CARBOXYLIC ACID COMPOUND OR SALT THEREOF, AND MEDICINAL USE THEREOF | THE GREEN CROSS CORPORATION (JP) | 1996-05-22 | — | — | EP | disclosed |
| US-5516913-A | Alcohols | HOFFMANN-LA ROCHE INC. (US) | 1996-05-14 | — | — | US | disclosed |
| US-5514801-A | TREATMENT OF AIDS | MONSANTO COMPANY (US) | 1996-05-07 | — | — | US | disclosed |
| US-5510388-A | TREATING HTLV, AIDS | G. D. SEARLE & CO. (US) | 1996-04-23 | — | — | US | disclosed |
| US-5510349-A | HUMAN IMMUNODEFICIENCY VIRUS | G.D. SEARLE & CO. (US) | 1996-04-23 | — | — | US | disclosed |
| US-5510378-A | Retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1996-04-23 | — | — | US | disclosed |
| US-5510487-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1996-04-23 | — | — | US | disclosed |
| US-5508294-A | USED TO TREAT HIV INFECTION | G.D. SEARLE & CO. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5508430-A | Oxirane intermediates for novel alcohols | HOFFMANN-LA ROCHE INC. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5488115-A | Alcohols | HOFFMANN-LA ROCHE INC. (US) | 1996-01-30 | — | — | US | disclosed |
| US-5475013-A | Inhibit human immunodeficiency virus protease | MONSANTO COMPANY (US) | 1995-12-12 | — | — | US | disclosed |
| US-5475027-A | Retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1995-12-12 | — | — | US | disclosed |
| US-5463104-A | Treating human immunodeficiency virus infection | G. D. SEARLE & CO. (US) | 1995-10-31 | — | — | US | disclosed |
| US-5451678-A | Intermediates for viricides | HOFFMANN-LA ROCHE INC. (US) | 1995-09-19 | — | — | US | disclosed |
| US-5446161-A | Protease inhibitor, viricides | HOFFMANN-LA ROCHE INC. (US) | 1995-08-29 | — | — | US | disclosed |
| EP-0666842-A1 | HYDROXYETHYLAMINO SULFAMIC ACID DERIVATIVES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-08-16 | — | — | EP | disclosed |
| EP-0666841-A1 | SUCCINOYLAMINO HYDROXYETHYLAMINO SULFAMIC ACID DERIVATIVES USEFUL AS RETROVIRAL PROTEASE INHIBITORS. | SEARLE & CO (US) | 1995-08-16 | — | — | EP | disclosed |
| EP-0666843-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFAMIC ACIDS USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-08-16 | — | — | EP | disclosed |
| EP-0512343-B1 | Amino acid derivatives and their use as anti-viral agents | HOFFMANN LA ROCHE (CH) | 1995-08-02 | — | — | EP | disclosed |
| WO-1995019958-A1 | MALARIAL ASPARTIC PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-07-27 | — | — | WO | disclosed |
| US-5430041-A | Amino acid derivatives having antiviral activity | HOFFMANN-LA ROCHE INC. (US) | 1995-07-04 | — | — | US | disclosed |
| EP-0657419-A1 | Alcohols | F. HOFFMANN-LA ROCHE AG (CH) | 1995-06-14 | — | — | EP | disclosed |
| EP-0656887-A1 | HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-06-14 | — | — | EP | disclosed |
| EP-0656888-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-06-14 | — | — | EP | disclosed |
| EP-0656886-A1 | N-(ALKANOYLAMINO-2-HYDROXYPROPYL)-SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS. | SEARLE & CO (US) | 1995-06-14 | — | — | EP | disclosed |
| EP-0641325-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1995006030-A1 | HYDROXYETHYLAMINO SULPHONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-03-02 | — | — | WO | disclosed |
| WO-1994025046-A1 | METHOD OF COMBATING ACYCLOVIR-RESISTANT HERPES SIMPLEX VIRAL INFECTIONS | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-11-10 | — | — | WO | disclosed |
| WO-1994014793-A1 | CYCLIC SULFONE CONTAINING RETROVIRAL PROTEASE INHIBITORS | G. D. SEARLE & CO. (US) | 1994-07-07 | — | — | WO | disclosed |
| WO-1994010136-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFAMIC ACIDS USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1994-05-11 | — | — | WO | disclosed |
| WO-1994010133-A1 | SUCCINOYLAMINO HYDROXYETHYLAMINO SULFAMIC ACID DERIVATIVES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1994-05-11 | — | — | WO | disclosed |
| WO-1994010134-A1 | HYDROXYETHYLAMINO SULFAMIC ACID DERIVATIVES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1994-05-11 | — | — | WO | disclosed |
| EP-0346847-B1 | Amino acid derivatives | HOFFMANN LA ROCHE (CH) | 1994-05-11 | — | — | EP | disclosed |
| WO-1994004492-A1 | HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1994-03-03 | — | — | WO | disclosed |
| WO-1994004493-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1994-03-03 | — | — | WO | disclosed |
| WO-1994004491-A1 | N-(ALKANOYLAMINO-2-HYDROXYPROPYL)-SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1994-03-03 | — | — | WO | disclosed |
| WO-1993023379-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-11-25 | — | — | WO | disclosed |
| WO-1993018056-A1 | ISOSTERIC ANTIHERPES PEPTIDE DERIVATIVES | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-16 | — | — | WO | disclosed |
| EP-0560267-A1 | Isosteric antiherpes peptide derivatives | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-15 | — | — | EP | disclosed |
| EP-0558673-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-09-08 | — | — | EP | disclosed |
| CN-1068333-A | Has hydrazine analog derivative of pharmacologically active and preparation method thereof | CIBA GEIGY AG (CH) | 1993-01-27 | — | — | CN | disclosed |
| EP-0512343-A2 | Amino acid derivatives and their use as anti-viral agents | F. HOFFMANN-LA ROCHE AG (CH) | 1992-11-11 | — | — | EP | disclosed |
| US-5157041-A | Viricides | HOFFMANN-LA ROCHE INC. (US) | 1992-10-20 | — | — | US | disclosed |
| WO-1992008699-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| US-5068325-A | Dopaminergic systems as hypotensives, sedatives, antitussives and/or antiphlogistics | KARL THOMAE GMBH (DE) | 1991-11-26 | — | — | US | disclosed |
| EP-0432694-A2 | Aminoalcohols | F. HOFFMANN-LA ROCHE AG (CH) | 1991-06-19 | — | — | EP | disclosed |
| EP-0346847-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-12-20 | — | — | EP | disclosed |
| EP-0154190-A1 | Pyridones | MERCK PATENT GmbH (DE) | 1985-09-11 | — | — | EP | disclosed |
| US-4487772-A | CARDIOTONIC AGENTS | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| US-4468402-A | Carbostyril derivatives, process for producing the same and cardiotonic compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-28 | — | — | US | disclosed |
| US-4454130-A | CARDIOTONIC, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
| US-4438277-A | Hydronaphthalene derivatives | SANKYO COMPANY, LIMITED (JP) | 1984-03-20 | — | — | US | disclosed |
| US-4361515-A | Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1982-11-30 | — | — | US | disclosed |
| US-4361515-A | Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1982-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113945-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | CYP3A43, CYP2E1, CYP7A1 | TAAR1 3821/4885F2RL1 1171/4885MAOB 80/4885 |
| US-20050261273-A1 | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors | DNPEP, ASPH, PEPD | TAAR1 2372/4885F2RL1 705/4885MAOB 2000/4885 |
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | TAAR1 1466/4885F2RL1 1672/4885MAOB 1594/4885 |
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | NOS3, NOS2, NOS1 | TAAR1 558/4885F2RL1 3625/4885MAOB 160/4885 |
| US-20080103311-A1 | Retroviral protease inhibitors | PREP, DNPEP, SERPINB1 | TAAR1 4724/4885F2RL1 432/4885MAOB 2473/4885 |
| US-20080261935-A1 | 2\" OXO-VORUSCHARIN AND DERIVATIVES THEREOF | RNASE1, FUT6, VNN1 | TAAR1 4869/4885F2RL1 3114/4885MAOB 2467/4885 |
| US-12043639-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | PHOSPHO1, MBOAT7, PLTP | TAAR1 3720/4885F2RL1 3732/4885MAOB 4799/4885 |
| US-20060167012-A1 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | PPARG, PPARA, PPARD | TAAR1 1813/4885F2RL1 1914/4885MAOB 2314/4885 |
| US-20070123473-A1 | Glycosylated steroid derivatives with anti-migratory activity | NR5A1, NR3C2, MIF | TAAR1 4843/4885F2RL1 3591/4885MAOB 2861/4885 |
| US-20130217704-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 2D6 | CYP2D6, CYP2A6, CYP2B6 | TAAR1 4359/4885F2RL1 641/4885MAOB 172/4885 |
| US-20030216435-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | TAAR1 4610/4885F2RL1 1221/4885MAOB 3945/4885 |
| US-20140343078-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 2D6 | CYP2D6, CYP2A6, CYP2B6 | TAAR1 4359/4885F2RL1 641/4885MAOB 172/4885 |
| US-20200283478-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | TAAR1 4623/4885F2RL1 288/4885MAOB 1282/4885 |
| US-20060020009-A1 | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | HAT1, UBXN4, PRSS1 | TAAR1 4319/4885F2RL1 2539/4885MAOB 3870/4885 |
| US-20220056066-A1 | AMPHOTERICIN B DERIVATIVES WITH IMPROVED THERAPEUTIC INDEX | C9, AMPD3, C5 | TAAR1 2436/4885F2RL1 4167/4885MAOB 237/4885 |
| US-20040198989-A1 | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | TAAR1 4773/4885F2RL1 1279/4885MAOB 3225/4885 |
| US-20070191371-A1 | HETEROCYCLIC MODULATORS OF PPAR | PPARG, PPARD, PPARA | TAAR1 1270/4885F2RL1 1704/4885MAOB 2041/4885 |
| US-10883118-B2 | Agents for improved delivery of nucleic acids to eukaryotic cells | SNRPE, POLRMT, PHAX | TAAR1 3946/4885F2RL1 3558/4885MAOB 4733/4885 |
| US-20080176842-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | PRSS1, DNPEP, PREP | TAAR1 4689/4885F2RL1 1257/4885MAOB 3009/4885 |
| US-20030171423-A1 | Resistance-repellent retroviral protease inhibitors | SERPINB1, MMP7, MME | TAAR1 4532/4885F2RL1 419/4885MAOB 2434/4885 |
| US-20090023664-A1 | ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | DNPEP, ASPH, PREP | TAAR1 4177/4885F2RL1 1621/4885MAOB 3387/4885 |
| US-20060135581-A1 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ASPH, DNPEP, APP | TAAR1 1940/4885F2RL1 2339/4885MAOB 167/4885 |
| US-20150250768-A1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | HIF1AN, HAVCR2, NEU1 | TAAR1 3738/4885F2RL1 664/4885MAOB 38/4885 |
| US-20110312992-A1 | Inhibitors of C-Kit and Uses Thereof | KIT, CHUK, MASTL | TAAR1 4635/4885F2RL1 1973/4885MAOB 494/4885 |
| US-20140213637-A1 | Agents for Improved Delivery of Nucleic Acids to Eukaryotic Cells | SNRPE, POLRMT, PHAX | TAAR1 3946/4885F2RL1 3558/4885MAOB 4733/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | TAAR1 364/4885F2RL1 4465/4885MAOB 2140/4885 |
| US-20210009494-A1 | Menaquinol Compositions and Methods of Treatment | SDHA, SDHB, NDUFB7 | TAAR1 4422/4885F2RL1 3890/4885MAOB 646/4885 |
| US-20020111368-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | TAAR1 4610/4885F2RL1 1221/4885MAOB 3945/4885 |
| US-10968240-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | PHOSPHO1, MBOAT7, PLTP | TAAR1 3720/4885F2RL1 3732/4885MAOB 4799/4885 |
| US-10138497-B2 | Agents for improved delivery of nucleic acids to eukaryotic cells | SNRPE, POLRMT, PHAX | TAAR1 3946/4885F2RL1 3558/4885MAOB 4733/4885 |
| US-10155780-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | PHOSPHO1, MBOAT7, PLTP | TAAR1 3466/4885F2RL1 3616/4885MAOB 4801/4885 |
| US-10912768-B2 | Compounds and methods for treating influenza | HIF1AN, HAVCR2, NEU1 | TAAR1 3738/4885F2RL1 664/4885MAOB 38/4885 |
| US-20090029971-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | PPARG, PPARA, PPARD | TAAR1 1813/4885F2RL1 1914/4885MAOB 2314/4885 |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | TAAR1 1466/4885F2RL1 1151/4885MAOB 1030/4885 |
| US-20040034071-A1 | Thioaryl sulfonamide hydroxamic acid compounds | MMP10, MMP1, MMP3 | TAAR1 4714/4885F2RL1 154/4885MAOB 1634/4885 |
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | TAAR1 2079/4885F2RL1 1664/4885MAOB 3067/4885 |
| US-20030195229-A1 | Glucamine salts for treating hepatitis virus infections | UGGT1, GYS2, MGAT3 | TAAR1 870/4885F2RL1 4814/4885MAOB 898/4885 |
| US-20240000966-A1 | Lipid Compositions For In Vivo Delivery | CHMP4B, LIPA, CETP | TAAR1 4081/4885F2RL1 3312/4885MAOB 4825/4885 |
| US-20060149045-A1 | Steroid compounds with anti-tumor activity | CYP17A1, HSD17B7, NR5A1 | TAAR1 4468/4885F2RL1 4215/4885MAOB 2261/4885 |
| US-20160215012-A1 | AMPHOTERICIN B DERIVATIVES WITH IMPROVED THERAPEUTIC INDEX | C9, AMPD3, C5 | TAAR1 2436/4885F2RL1 4167/4885MAOB 237/4885 |
| US-20180078533-A1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | HIF1AN, HAVCR2, NEU1 | TAAR1 3738/4885F2RL1 664/4885MAOB 38/4885 |
| US-20070037754-A1 | Inhibitors of HIV protease; 2S-[[(N-methylamino)acetyl]amino]-N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino)-1S-(phenylmethyl)propyl]-3,3-dimethyl-butanamide | DNPEP, PREP, ANPEP | TAAR1 4729/4885F2RL1 456/4885MAOB 2544/4885 |
| US-20210177809-A1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | HIF1AN, HAVCR2, NEU1 | TAAR1 3738/4885F2RL1 664/4885MAOB 38/4885 |
| US-20100144738-A1 | INHIBITORS OF C-MET AND USES THEREOF | MET, HGF, HGFAC | TAAR1 3269/4885F2RL1 1428/4885MAOB 1139/4885 |
| US-20060276493-A1 | alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | TAAR1 4168/4885F2RL1 1789/4885MAOB 3403/4885 |
| US-20200289456-A1 | METHODS FOR INHIBITING TUMORS AND DRUG RESISTANCE | HCCS, CYP2E1, CYP7A1 | TAAR1 4447/4885F2RL1 3268/4885MAOB 902/4885 |
| US-10188605-B2 | Nanoparticles and nanoparticle compositions | MCM6, MPI, MSH2 | TAAR1 3991/4885F2RL1 3559/4885MAOB 3106/4885 |
| US-20050119338-A1 | Combination of cytochome p450 dependent protease inhibitors | CYP27A1, CYP11A1, PITRM1 | TAAR1 4723/4885F2RL1 549/4885MAOB 989/4885 |
| US-10550153-B2 | Peptide or pharmaceutically acceptable salt thereof, or prodrug thereof | NMUR2, NMUR1, NTSR2 | TAAR1 691/4885F2RL1 488/4885MAOB 3480/4885 |
| US-20190307730-A1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | HIF1AN, HAVCR2, NEU1 | TAAR1 3738/4885F2RL1 664/4885MAOB 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.